The latest market report published by Credence Research, Inc. “Global Chronic Idiopathic Constipation (CIC) Drugs Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016-2022,” the chronic idiopathic constipation (CIC) drugs market was valued at USD 1675.4 Mn in 2015, and is expected to reach USD 2570.8 Mn by 2022, expanding at a CAGR of 6.4% from 2016 to 2022; where Europe has the largest market share.
Browse the full report at http://www.credenceresearch.com/report/chronic-idiopathic-constipation-cic-drugs-market
Chronic idiopathic constipation (CIC) is a common gastrointestinal disorder. The currently available treatment options, both prescription based and OTC have demonstrated limited efficacy in a considerable set of patients. Thus there is a major demand for more effective medications for the treatment of CIC. Linaclotide is a secretagogue and has novel action mechanism; it has low oral bioavailability and has demonstrated the least systemic side effects. Through several clinical trials, Linaclotide has demonstrated greater efficacy in treating both CIC and irritable bowel syndrome induced constipation.
Currently North America is the largest regional market for CIC drugs at a market share of approximately 50%. It is also expected that the region will progress at the fastest CAGR of above 8% during the forecast period. Higher awareness among physicians and patient population significantly contribute the market growth in the region. Earliest commercialization of the drug in the US also adds up to the high demand of the drug in North America market. On the other hand, gradual introduction of Linaclotide in other developing markets will facilitate market growth in Asia Pacific market. China, Japan, Australia and India are the major national markets that are expected to give highest revenue contributions to the Asia Pacific CIC drugs market. Also, supporting the established fact of correlation between age and risk of CIC, it is reported that China and Japan will be the largest national markets for CIC drugs in Asia Pacific.
Overall, the CIC drugs market is open for further innovations, anticipating introduction of novel therapeutic options in the global market. Intensive research and development activities undertaken by the major market players indicate further competition in the market in the next ten years.
Chapter 1 Preface
1.1 Report Scope and Description
1.2 Research Methodology
Chapter 2 Executive Summary
Browse For The Sample Page @ http://www.credenceresearch.com/sample-request/57738
Chapter 3 Global CIC Drugs Market Analysis
3.1 CIC Drugs Market Overview
3.2 Market Inclination Insights
3.3 Attractive Investment Proposition, 2015
3.4 Market Dynamics
22.214.171.124 Adverse health effects from modern dietary habits
126.96.36.199 Cancer or other systematic disease
188.8.131.52 Increasing geriatric population
184.108.40.206 Better and effective drugs in pipeline
220.127.116.11 Increasing constipation problems as a side-effect frequently prescribed medicines
18.104.22.168 Surgical treatments
22.214.171.124 Unawareness and Ignorance among people
126.96.36.199 Side-effects of the chronic idiopathic constipation drugs
188.8.131.52 Emerging APAC market
184.108.40.206 High unmet needs
3.5 Attractive Investment Proposition, 2015
3.6 Market Positioning of Key CIC Drugs Manufacturers
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Name: Chris Smith
Designation: Global Sales Manager